TITLE

Availability of information for dosing injectable medications in underweight or obese patients

AUTHOR(S)
Jacques, Kimberly A.; Erstad, Brian L.
PUB. DATE
November 2010
SOURCE
American Journal of Health-System Pharmacy;11/15/2010, Vol. 67 Issue 22, p1948
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. Product information and pivotal studies on newly marketed injectable medications were reviewed to determine whether a weight descriptor was included and if information was provided for dosing patients with extremes of body weight. Methods. Products with new drug applications approved by the Food and Drug Administration between January 1, 2004, and January 30, 2009, were evaluated. Any information related to weight descriptors or dosing of patients with extremes of weight (body mass index of <18.5 or >40 kg/m2) relative to age and height was extracted from the product labeling or pivotal studies. Pharmaceutical companies were contacted if pivotal studies had not been published. The information was evaluated with a dosing usefulness score of 0--3; a score of 2 or greater was considered minimally adequate for dosing patients with extremes of weight. Results. Of the 84 medications evaluated, some reference to weight descriptors was found for 23 (27%). None had a calculated usefulness score of 2 or above based on information from product information or pivotal trials. Conclusion. Information from product labeling and pivotal studies involving newly marketed injectable medications is inadequate for dosing patients with extremes of weight.
ACCESSION #
55041400

 

Related Articles

  • Alirocumab approved to help lower LDL cholesterol. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;9/1/2015, Vol. 72 Issue 17, p1428 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the marketing of alirocumab injection on July 24, 2015 or Praluent as an add-on cholesterol-lowering treatment for adults with plasma low-density lipoprotein cholesterol (LDL-C) concentration needs to be even lower....

  • FDA actions. Elliott, William T. // Primary Care Reports;Jun2012 Pharmacology Watch, p2 

    The article reports that the FDA has approved Avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction (ED), and requires a labeling change on finasteride which is a Merck's testosterone blocker.

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Jun2012, Vol. 47 Issue 6, p471 

    Several tables are presented which provide data related to drug approvals, subsmission, and labeling which include the new drugs being approved by the U.S. Food and Drug Administration (FDA) from March 17 to April 13, 2012, newly FDA-approved dosage forms and indications from March 17 to April...

  • New molecular entities.  // Formulary;Jul2005, Vol. 40 Issue 7, p210 

    Provides information on drugs that were approved by the United States Food and Drug Administration. Exenatide injection; Tigecycline antibiotic; Tipranavir.

  • FDA actions.  // Primary Care Reports;Feb2013 Pharmacology Watch, p2 

    The article reports on the approval of the pasireotide diaspartate injection marketed by Novartis AG as Signifor by the U.S. Food and Drug Administration (FDA) for the treatment of Cushing's disease in patients who are not in line for surgery and for those patients whose surgery has not worked.

  • Makena.  // Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p11 

    The article reports on the decision of the U.S. Food & Drug Administration (FDA) to approve Makena injection to reduce the risk of preterm delivery before 37 weeks of pregnancy.

  • FDA actions in brief.  // Formulary;Dec2008, Vol. 43 Issue 12, p434 

    The article focuses on the approval of drugs by the U.S. Food and Drug Administration (FDA). Muscairinillc receptor antagonist has been approved for the treatment of overactive bladder. Fesoterodine is a muscarinic receptor antagonist which produces its effects by inhibiting the receptors that...

  • New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidence. Miller, Brien Rex; Hanh Nguyen; Jia-Haur Hu, Charles; Chihyi Lin; Quang T. Nguyen // American Health & Drug Benefits;Nov2014, Vol. 7 Issue 8, p452 

    BACKGROUND: Diabetes is a deadly and costly disease. The number of adults in the United States with newly diagnosed diabetes has nearly tripled from 1980 to 2011. At the current pace, 1 in 3 US adults will have diabetes in their lifetime. Currently, 14 classes of drugs are available to treat...

  • LEGAL & REGULATORY: Herbal Experts Say CSPI Petition for St. John's Wort Warning Inaccurate. Stafford, Lindsay // HerbalGram;Feb-Apr2012, Issue 93, p58 

    The article reports on a November 2011 decision which the Center for Science in the Public Interest made to urge the U.S. Food and Drug Administration to require detailed warning labels on all St. John's wort products, which are used to treat depression, sleep disorders, anxiety and other...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics